Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4859MR)

This product GTTS-WQ4859MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Follicular lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4859MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4677MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-986089
GTTS-WQ829MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-155
GTTS-WQ3738MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ1374MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-874
GTTS-WQ7942MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ4469MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-901608
GTTS-WQ7253MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA FP-1302
GTTS-WQ6222MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CR4098
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW